Showing posts with label nppa. Show all posts
Showing posts with label nppa. Show all posts

Wednesday, 15 February 2017

NPPA Stent Notification

NPPA Stent Notification

(Published in Part II, Section 3, Sub Section (ii) of the Gazette of India Extraordinary)
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceuticals Pricing Authority
New Delhi. The 13. February 2017

S.O. 412(E) Whereas the Government of India in the Ministry of Health and Family Welfare included Coronary Stents in the National List of Essential Medicines. 2015 (NLEM, 2015) by notification
No. X-11035/344/2015-DFQC dated 19th July 2016.

2. And whereas the Government of India in the Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, by notification No. S.O. 4100 (E) dated 21st December 2016 has incorporated Coronary Stents at serial no. 31 of Schedule I of the Drug Prices Control Order, 2013 (DPCO, 2013) and therefore, Coronary Stems arc 'scheduled formulations under the provisions of the DPCO, 2013.

3. And whereas die National Pharmaceutical Pricing Authority (NPPA) was established by Resolution No. 33/7/97-PI.I dated 29. August 1997 of the Government of India in the Ministry of Chemicals and Fertilizers to fix/revise, monitor prices of drugs/formulations and oversee the implementation of the DPCO; and whereas the Government of India by S.O. 1349(E) dated 30th May 2013 in exercise of the powers conferred by Section 3 and 5 of the Essential Commodities Act, 1955 (10 of 1955) has delegated the powers in respect of paragraphs 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29,30 and 32 of the DPCO, 2013 to the NPPA to exercise the functions of the Central Government.

4. And whereas the aim of the DPC. 2013 issued under section 3 of Essential Commodities Act, 1955, is to ensure that essential drugs are available to all at affordable prices. Whereas the Hon'ble Supreme Court of India by order dated 12th November 2002 in SLP no. 3668/2003 (Union of India vs. K.S. Gopinath & others) directed the Government to ensure that life saving drugs do not fall out of price control.

5. And whereas the Core Committee which examined the issues relating to the essentiality of Coronary Stems in its report to the Government in April 2016 observed that there is very high incidence of coronary artery disease (CAD) in India associated with high morbidity and mortality; and that CAD has become a major public health problem; and that Percutaneous Coronary Intervention (PCI) procedure requiring coronary stent implantation is an important treatment modality for the management of CAD, and hence coronary stents are 'essential' for public health.

6. And whereas NPPA carried out an exhaustive exercise of consultation with stakeholders for fixing the ceiling price of Coronary Stents on 4th January 2017, 5th January 2017 and 6th January 2017, as per office memorandum no. 19(837)/2016/Div.11/DP/NPPA dated 23rd December 2016; and whereas NPPA considered all available information and data on prices of Coronary Stents in its 40th Authority Meeting held on 23rd January 2017. During deliberations, it was found that huge unethical markups are charged at each stage in the supply chain of Coronary Stents resulting in irrational, restrictive and exorbitant prices in a failed market system driven by information asymmetry between the patient and doctors pushing patients to financial misery; and whereas under such extraordinary circumstances, there is an urgent necessity, in public interest, to fix ceiling price of Coronary Stents to bring respite to patients.

7. And whereas the Hon’ble Supreme Court of India in its judgment in Glaxo India Limited vs UOI reported in (2014)2 SCC 753, while dealing with the implementation of notified prices for the benefit of consumers, referred to the prefatory statement made by the Hon’ble Supreme Court in Cynamide India Limited (1987) 2 SCC 722 as worth noticing, wherein the Court observed:

“2. Profiteering by itself. is evil Profiteering in the scares resources of the community, much needed life-sustaining foodstuffs and life-saving drugs is diabolic It is a menace which has to be fettered and curbed. One of the principal objectives of the Essential Commodities Act. 1955 is precisely that. It must be remembered that Article 39(b), enjoins a duty on the State towards securing 'that the ownership and control of the material resources of the community are so distributed as best to subserve the common good”.
8. And whereas the Government is under constitutional obligation to provide fair, reasonable and affordable price for Coronary Stents and therefore its immediate intervention is imperative to check unethical profiteering and exploitive pricing; and whereas Paragraph 19 of the DPCO, 2013 inter- alia authorises the Government, extraordinary circumstances, if it considers necessary so to do in public interest, to fix the ceiling price or retail price of any drug for such period, as it deems fit.

9. And whereas price fixation notifications issued for certain formulations under paragraph 19 of the DPCO, 2013 by the NPPA on 10th July 2014 have been upheld by the Hon'ble High Court of Bombay in its judgment dated 26th September 2016 in W.P.(C) No. 2700 of 2014 (Indian Pharmaceutical Alliance vs. Union of India) wherein the Hon'ble High Court. inter-alia, observed:
“20…… when such failure is considered in the context of role the pharmaceuticals play in the area of public health, which is a social right, the Government intervention becomes necessary especially when exploitive pricing makes medicines tin-affordable and beyond the reach of most and also puts huge financial burden in terms of out of pocket expenditure on healthcare....”
and whereas SLP (C) 30089/2016 filed by Indian Pharmaceutical Alliance has been dismissed on 24th October 2016 by the Hon’ble Supreme Court of India.

10. And whereas W.P.(C) 1772/2015 (PIL) and W.P. (C)11085/2016 have been filed in nature of Public Interest Litigation (PIL) including Cont. Case (C.) 815/2015 before the Hon’ble High Court of Delhi seeking directions to the Respondents (Union of India) to include Coronary Stents in the National List of Essential Medicines (NLEM) and thereby control the sale price of Coronary Stents.

11. And whereas, the NPPA in its Authority Meeting held on 13th February 2017, after duly examining in detail and considering all available information/data and all relevant options for price fixation of Coronary Stents, under present extraordinary circumstances of a failed and exploitative market system has decided that it is immediately necessary to fix ceding prices of Coronary stents in order to protect public interest.

12. Now, therefore, in the exercise of the powers delegated by Government of India in the Ministry of Chemicals and Fertilizers under paragraph 19 of the Drugs (Prices Control) Order. 2013 by S.O. No. 1394(E) dated 30th May 2013, the Government having been satisfied in view of extraordinary circumstances as explained above, that it is necessary to do in public interest, hereby fixes and notifies the ceiling prices, exclusive of local tax applicable, if any, in respect of Coronary Stents, as specified below:
TABLE

Sl. No.
Coronary Stents (Sl. 31 in Schedule I of DPCO, 2013
Unit (In Number)
Ceiling Price (In Rs.)
(1)
(2)
(3)
(4)
1.
Bare Metal Stents
1
7260

2.
Drug Eluting Dents (DES) including metallic DES and Bioresorbable Vascular Scaffold (BSV), Biodegradable Stents
1
29600

Note:

(a) The ceiling prices specified in column (4) of the above table shall be applicable from the date of publication of notification in the Gazette of India Extraordinary and shall also be applicable to all the stocks of Coronary Stents available for sale in the trade channel.

(b) All manufacturers of Coronary stents, selling branded or non-branded or both versions of gents at prices higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the price of all such stems downward not exceeding the ceiling price specified in column (4) in the above table, plus local taxes as applicable and paid, if any

(c) All manufacturers/marketers of Coronary Stents having MRP lower than the ceiling price specified in column (4) in the above table plus local taxes as applicable and paid, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(d) The manufactures may add local taxes/VAT and no other charges in the calculation of MRP if they have actually paid such taxes or if it is payable to the Government on the ceiling price specified in column (4) of the above said table in paragraph (12) of this order.

(e) The ceiling price for a pack of coronary stent shall be arrived at by concerned manufacturer/importer in accordance with the ceiling price specified in column (4) of the above table as per the provisions under DPCO, 2013.

(f) The manufacturers under Paragraph 24 of DPCO, 2013 shall issue price list in Form—V as prescribed in Schedule II of the DPCO, 2013 to the NPPA online through Integrated Pharmaceutical Database Management System (IPDMS) and submit a copy to all State Drug Controllers and all distributors/dealers/retailers. They shall also furnish quarterly return to the NPPA, in respect of production / import and sale of Coronary Stents in Form - III as prescribed in Schedule-II of the DPCO, 2013 through IPDMS.

(g) As per paragraph 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplement, price list, if any, as furnished by the manufacturer/importer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(h) Wherever institutions such as hospitals/nursing homes/clinics performing cardiac procedures using Coronary Stents are billing directly to the patients, they shall be required to comply with the ceiling prices notified hereinabove and follow the applicable provisions of the DPCO, 2013 including(g) above.

(i) Institutions such as hospitals/nursing homes/clinics utilizing Coronary Stents shall specifically and separately mention the cost of coronary gent along with its brand name, name of the manufacturer/importer/batch no. and other details, if any, in their billing to the patients or their representatives.

4) The ‘manufacturer’ for the purpose of this order means person who manufactures or imports or markets Coronary Stents for distribution or sale in the country.

(k) Any manufacturer or institution or person not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order. 2013 read with Essential Commodities Act, 1955.

13. The ceiling price fixed hereinabove shall be maintained for a period of one year from date of this notification, unless revised by another gazette notification.

14. Any manufacturer intending to discontinue production or import of Coronary Stents shall furnish information to the NPPA, in respect of discontinuation of production and /or import in Forrn-1V of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation as prescribed under paragraph 21(2) of the DPCO, 2013 and follow the ceiling price till clearance from the Government.

PN/I73/41/2017
F.No.8 (4I)/2017/DP/NPPA/Div II
(Dr. Sharmila Mary Joseph K)
Member Secretary,
National Pharmaceutical Pricing Authority 

Sunday, 12 February 2017

Compulsory columns in a medical prescription

Compulsory columns in a medical prescription A prescription is an integral part of a consultation as it summarizes the instructions of the doctor to the patient. The Free Dictionary has defined a prescription as “a written directive, as for the compounding or dispensing and administration of drugs, or for other service to a particular patient” (http://medical-dictionary.thefreedictionary.com/prescription). Handing over of the prescription by the doctor to the patient marks the conclusion of every consultation, be it a new consultation or a follow up visit. A medical prescription traditionally enumerates the drugs that have been prescribed, along with directions for the patient to follow when taking the drug and the diagnosis. Some significant clinical findings may also be mentioned. There are four parts of a typical prescription • Superscription: Indicated by the sign Rx meaning recipe, take • Inscription: This is the main part of the prescription, contains the names, doses and dosage forms of drugs ordered. • Subscription: Directions for compounding of drugs • Signature: Instructs the patient about how to take the drugs prescribed and is preceded by the symbol S or Sig (signature - Latin) Noncommunicable diseases (NCDs) such as heart disease, stroke, cancer, diabetes and chronic lung disease are a major public health problem now incurring significant costs in their management. The Global Status Report on Noncommunicable Diseases 2010 by the WHO states that “NCDs are caused, to a large extent, by four behavioral risk factors that are pervasive aspects of economic transition, rapid urbanization and 21st-century lifestyles: tobacco use, unhealthy diet, insufficient physical activity and the harmful use of alcohol”. Given the alarmingly high prevalence of lifestyle diseases worldwide, including India, it’s now time to move beyond the confines of the traditional way of writing a prescription. In addition to the demographic data and drugs, a prescription should have some ‘compulsory columns’. • Hygiene • Vaccines • Addictions • Noise pollution • Standard Lifestyle • Rehabilitation: Exercise, job, vacation • Counselling: Diet, mental health, exercise • Point of Care Investigations: ECG, blood sugar, pocket spirometry, urine spot test, hemoglobin, blood counts, coagulation etc. • Noise pollution check • Air pollution check: PM 2.5, PM 10 • Important phone numbers: Police, hospitals, ambulance, fire department, emergency number (Similar to 911 in US, the single national emergency number in India is 112) Adding these components to a prescription is an intervention towards ‘preventive healthcare’, primary prevention or secondary prevention and check the rising prevalence of chronic lifestyle diseases. This way doctors can motivate their patients and support them to make healthier lifestyle choices. Dr KK Aggarwal National President IMA & HCFI

Saturday, 11 February 2017

IMA So far

IMA So far Greetings from IMA HQs! Since the Team Digital IMA took over, we have achieved the following in the past 40 days: • In the PCPNDT Act, IMA is pursuing the Ministry to exclude clerical errors under Penal Provisions. • IMA is pursuing Ministry of Health to exclude single doctor establishment out of Clinical Establishment Act (CEA). • IMA has been able to pursue the Govt. of India to write to all States to enact special Laws, where absent, in their respective states to tackle violence against medical profession and medical establishments and requested their strict implementation, where present. • On IMA’s persuasion the government will recommend to Consumer Ministry to cap medical compensation. • IMA 1 Voice Satyagraha, IMA 1 Voice Solidarity day and IMA 1 Voice Action Day was a great success • IMA is in process of starting certifying IMA Clinics involving all national health programs. • IMA has finalized IMA Prayer. • Kerala State government has included noise and health as a Chapter in 8th standard syllabus on IMA’s recommendations. • On IMA’s intervention, 304-B was converted into 304-A in Pune case. • On IMA’s intervention, the 3 attempts for UG MBBS admission were shifted from retrospective to prospective. The Ministry of Tourism, Govt of India has been persuaded by IMA for the following: • Duration of e-medical visa to be 6 months, with double entry. • Attendants traveling with patients to be made eligible for e-medical visa on automatic route with a simplified online application procedure. • Hospitals to be responsible for reporting of personal details of patients to FRRO (Foreign Regional Registration Office) in lieu of present system of personal reporting. • Requirement of referral letter from local doctor may be dropped. • Visa fee for e-medical visa to be rationalized. • Concerned agencies to expedite accreditation process and issue of accreditation letters with respect to treatment at Ayurveda and Wellness centers. • Clear indication of the broad cost of various treatments readily available for the patients; hospitals should have all inclusive packages advertised within a band. • Under the purpose of visit for e-TV category, a separate check box to be included for Medical Attendant and that this could then be linked with documentation of the original applicant for the e-Medical Visa so that it could be clearly established who is coming in as the attendant. • e-Medical Visa on the basis of invitation letters from NABH-accredited hospitals. • Separate immigration counters at major international airports for e-Medical Visas • A facilitation counter for such tourists outside the immigration area under the aegis of the Ministry of Health and Family Welfare (MoHFW) and the Hospital Association with interpreters for Russian and Arabic languages. • NABH may set up such counters. The counter could also be connected to the MoT Helpline number 1363 for multi-language assistance, which is 24X7 service for tourists. • The cost of e-Medical Visa should be on par with that of the Tourist Visa. • MHA may be requested to include at least one Medical Attendant who could accompany the patient on the e- Medical Visa and that the visa application for the attendant be linked with that of the patient (e-Medical Visa applicant) The aim of every State of IMA should be to act locally and think nationally. Let’s all join hands together with IMA HQs and solve all national issues in the coming months.

Friday, 10 February 2017

Jaroorat Bhi Hai Kya? Rationalization of clinical practice

Jaroorat Bhi Hai Kya? Rationalization of clinical practice The practice of medicine today relies a lot on diagnostic investigations as an aid to diagnosis and management. The fact that the medical profession was placed under the purview of the Consumer Protection Act, may certainly have contributed to this trend. But, practicing ‘defensive’ medicine by overinvestigating a patient may not help the patient as they could lead to false positive results. The number of tests may make the patients more anxious. They also add to the healthcare costs, which should be a matter of concern for a country like ours, where patients pay most of their medical expenses out of their own pockets. Prescribing too many and at times unnecessary tests overburdens the healthcare system translating into an inefficient healthcare system. The Choosing Wisely campaign launched in 2012 was a step forward to avoid medical tests, treatments and procedures. The campaign aims “to promote conversations between clinicians and patients by helping patients choose care that is: Supported by evidence, not duplicative of other tests or procedures already received, free from harm and truly necessary (www.choosingwisely.org)”. Non-maleficence (do no harm) and beneficence (do good) are the pillars of medical ethics. As clinicians, it is our duty to provide the safest, cheapest but quality drug to our patients and prescribe the right investigation to the right patient. “Jaroorat Bhi Hai Kya” is a campaign of the Indian Medical Association (IMA) to promote rational use of drugs and/or rational ordering of investigations and hospitalizations. This will help avoid litigations. Rational use of drugs assumes importance particularly in view of the widely prevalent problem of antibiotic resistance globally. Extensive and injudicious use of antibiotics has been a major factor driving this public health crisis. Be cautious about off-label use of drugs, procedures. This may be considered a trial and need approval of Ethics Committee. Before you prescribe any drug or order investigations, ask yourself the following questions: • Is it necessary? • Will it benefit my patient? • Is it safe? Remember, Think before you Ink …Use Wisely and not widely…

Thursday, 9 February 2017

Updated ACIP Immunization Schedule for Adults

Updated ACIP Immunization Schedule for Adults The Advisory Committee on Immunization Practices (ACIP) has released updated immunization schedule for adults aged 19 years or older, United States, which have been published February 7, 2017 in the Annals of Internal Medicine. • ACIP recommends against live attenuated influenza vaccine (LAIV) during the 2016–2017 influenza season. • Adults with a history of egg allergy who have only hives after exposure to egg should receive age-appropriate inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV). • Healthy adolescents who start their human papillomavirus vaccine (HPV) series before age 15 years are recommended to receive 2 doses of HPV. But, for adults and adolescents who did not start their vaccination series before age 15 years, 3 doses are recommended. • Hepatitis B vaccine is recommended for adults with chronic liver disease, including, but not limited to, hepatitis C virus infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, and an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level greater than twice the upper limit of normal. • A 2-dose primary series of serogroups A, C, W, and Y meningococcal conjugate vaccine is recommended for adults with HIV infection. • Three doses of MenB-FHbp are recommended for adults at increased risk for meningococcal disease and for use during serogroup B meningococcal disease outbreaks, while 2 doses have been recommended for healthy adolescents and young adults who are not at increased risk for meningococcal disease. (Source: Ann Intern Med. 2017;166(3):209-219)

Monday, 22 August 2016

With price cap, 22 drugs get cheaper

With price cap, 22 drugs get cheaper In a move that would make some commonly used cancer drugs, anti-retrovirals and medicines to treat malaria cheaper by up to 45%, the central drug regulator has capped prices of 22 essential medicines with immediate effect. The price cap announced by National Pharmaceutical Pricing Authority (NPPA) would bring down maximum retail price or MRP of these medicines down by 10-45%. It is likely to impact prices of nearly 220 medicine brands containing 22 formulations. For instance, the price of 1ml Doxorubicin HCl Pegylated Liposomal Injection — used in the treatment of different types of cancer including blood, breast, stomach, lungs, ovaries and kidneys — has been fixed at Rs 723.93, whereas a pack of Zoledronic Acid infusion — used with cancer chemotherapy to treat bone problems — will now cost Rs 3,609.13. "The average price reduction on these drugs would be at least 25% after the latest order," an official told TOI. The NPPA caps prices of essential drugs at the simple average of all medicines in a particular therapeutic segment with sales of more than 1%. [TOI]